清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 4418: Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9

作者
Rui Liu,Lan Ding,Yushi Chi,Ge Song,Kuichao Qu,W.-J. Yang,Kun Yan,Jinbo Liu,Huixin Yan,Xiaoling Yuan,Ying Chen,Zhenjian Li,Chen Hu,Jijun Yuan
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 4418-4418
标识
DOI:10.1158/1538-7445.am2026-4418
摘要

Abstract Introduction: ADAM metallopeptidase domain 9 (ADAM9), a member of the disintegrin and metalloproteinase, mediates proteolytic shedding of cytokines and growth factors. ADAM9 dysregulation promotes tumor progression, metastasis, and pathological angiogenesis. ADAM9 is overexpressed in various solid tumors, including pancreatic, lung, gastric, and breast cancers, with low expression in normal adult tissues. Previously, the clinical development of ADAM9-targeted ADC IMGC-936 was terminated due to maytansinoid-related ocular toxicities. Herein, we developed a next-generation ADAM9 ADC using a camptothecin-based linker-payload, which is anticipated to avoid ocular toxicity and possess expanded therapeutic index. Methods: ADC cytotoxicity was evaluated using the CellTiter-Glo (CTG) assay in Jurkat (ADAM9-negative), Calu-3 (intermediate ADAM9 expression), and NCI-H1693 (high ADAM9 expression) cell lines. Bystander activity was assessed in Jurkat cells co-cultured with CHOK1-hADAM9 cells, with Jurkat viability determined by CTG. ADC stability in human and rat plasma was monitored over 14 days, with payload release quantified by LC-MS. Accelerated stability was examined by incubating ADCs at 25 °C for 7 days, followed by drug antibody ratio (DAR) and size exclusion chromatography monomer fraction analysis. In vivo efficacy was investigated in Calu-3 (non-squamous NSCLC, EGFR wildtype) and DLD-1 (CRC, MSI-H, KRAS G13D) cell line-derived xenograft (CDX) mouse models. A PK study was conducted in Sprague-Dawley rats administered intravenously with ADAM9 ADC 5 mg/kg. Results: The parental antibody exhibited nanomolar affinity for human and cynomolgus ADAM9, with no cross-reactivity to rodent orthologs or other ADAM family members. Antibody internalization in MKN-45, MiaPaCa-2, and Calu-3 cells were time-dependent and highly efficient (>50% at 4 h), while the ADC showed comparable or enhanced internalization. The ADAM9-ADC demonstrated potent cytotoxicity and bystander killing effects. In Calu-3 CDX models, a single 3 mg/kg dose elicited 109.3% tumor growth inhibition (benchmark ADC, 91.1%). In DLD-1 CDX models, TGIs reached 90.2% and 66.8% at 3 and 8 mg/kg, respectively, significantly outperforming the benchmark (39.2%) at 3mg/kg. The ADC also displayed excellent plasma stability, with minimal DAR reduction and aggregation in accelerated and freeze-thaw stability assays. The ADAM9 ADC also exhibited a favorable pharmacokinetic profile in rats, characterized by minimal free toxin release and antibody-like half-life. Conclusion: Preclinical studies reveal that the ADAM9-ADC exhibits potent in vitro cytotoxicity and superior in vivo antitumor efficacy relative to benchmarks. Pilot toxicology studies in cynomolgus monkeys are ongoing. Further clinical development is warranted. Citation Format: Rui Liu, Lan Ding, Yushi Chi, Ge Song, Kuichao Qu, Wan-jen Yang, Kun Yan, Jinbo Liu, Huixin Yan, Xiaoling Yuan, Ying Chen, Zhenjian Li, Chen Hu, Jijun Yuan. Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4418.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
西瓜柠檬可乐完成签到 ,获得积分10
11秒前
李煜琛完成签到 ,获得积分10
19秒前
悦耳的竺完成签到 ,获得积分10
19秒前
搜集达人的应助被冲冲冲采纳,获得10
20秒前
大力的安阳完成签到 ,获得积分10
23秒前
无花果的应助被ZLPY采纳,获得30
23秒前
30秒前
30秒前
刘亚梅完成签到 ,获得积分10
33秒前
醉熏的小凡完成签到,获得积分10
35秒前
冲冲冲发布了新的文献求助10
36秒前
apt完成签到 ,获得积分10
40秒前
46秒前
忧伤的白秋完成签到,获得积分10
48秒前
51秒前
lx完成签到 ,获得积分10
57秒前
天天快乐的应助被hilufite采纳,获得10
1分钟前
nhzz2023完成签到 ,获得积分10
1分钟前
和谐如彤完成签到,获得积分10
1分钟前
nanjing01完成签到 ,获得积分10
1分钟前
如泣草芥完成签到,获得积分10
1分钟前
Jessie完成签到,获得积分10
1分钟前
RZH发布了新的文献求助50
1分钟前
hy发布了新的文献求助10
1分钟前
笙歌完成签到 ,获得积分10
1分钟前
点点完成签到 ,获得积分10
1分钟前
细胞呵呵完成签到 ,获得积分10
1分钟前
cc发布了新的文献求助10
1分钟前
1分钟前
长孙烙完成签到 ,获得积分10
1分钟前
菜鸟学习完成签到 ,获得积分10
1分钟前
wayne完成签到 ,获得积分0
1分钟前
junio完成签到 ,获得积分10
1分钟前
威武的迎蓉完成签到,获得积分10
2分钟前
慎独而已完成签到,获得积分10
2分钟前
gzhy完成签到,获得积分10
2分钟前
2分钟前
科研通AI65的应助被RZH采纳,获得10
2分钟前
充电宝的应助被慎独而已采纳,获得10
2分钟前
馄饨炖饺子完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697